I-MAB is a clinical-stage biotech company... Show more
On November 03, 2025, the Stochastic Oscillator for IMAB moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 69 instances where the indicator left the oversold zone. In of the 69 cases the stock moved higher in the following days. This puts the odds of a move higher at over .
a clinical stage biopharmaceutical company, which engages in developing and commercialization of differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders.
Industry Biotechnology